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ABSTRACT: The risk of serious bleeding is a major liability
of anticoagulant drugs that are active-site competitive
inhibitors targeting the Factor Xa (FXa) prothrombin (PT)
binding site. The present work identifies several new classes of
small molecule anticoagulants that can act as nonactive site
inhibitors of the prothrombinase (PTase) complex composed
of FXa and Factor Va (FVa). These new classes of
anticoagulants were identified, using a novel agnostic
computational approach to identify previously unrecognized
binding pockets at the FXa-FVa interface. From about three
million docking calculations of 281 128 compounds in a
conformational ensemble of FXa heavy chains identified by
molecular dynamics (MD) simulations, 97 compounds and their structural analogues were selected for experimental validation,
through a series of inhibition assays. The compound selection was based on their predicted binding affinities to FXa and their
ability to successfully bind to multiple protein conformations while showing selectivity for particular binding sites at the FXa/FVa
interface. From these, thirty-one (31) compounds were experimentally identified as nonactive site inhibitors. Concentration-
based assays further identified 10 compounds represented by four small-molecule families of inhibitors that achieve dose-
independent partial inhibition of PTase activity in a nonactive site-dependent and self-limiting mechanism. Several compounds
were identified for their ability to bind to protein conformations only seen during MD, highlighting the importance of accounting
for protein flexibility in structure-based drug discovery approaches.
■ INTRODUCTION
The blood coagulation system represents the first line of
defense against blood loss following injury. This system consists
of a cascade of circulating inactive serine protease zymogens, as
well as regulatory cofactors and inhibitors. Each active enzyme,
once generated from its zymogen, specifically cleaves the next
zymogen in the cascade pathway to produce an active protease,
a process that is repeated until, finally, thrombin cleaves the
fibrinopeptides from fibrinogen to produce fibrin, which
polymerizes to make a blood clot. The amplification provided
by this system leads to the potential for explosive clot
formation.1 Although efficient clotting limits the loss of blood
at a site of trauma, it also poses the risk of systemic coagulation,
resulting in massive thrombosis. This can result in myocardial
infarction, unstable angina, atrial fibrillation, stroke, pulmonary
embolism and deep vein thrombosis. Several new direct Factor
Xa (FXa) inhibitors have received approval for clinical use in
anticoagulant therapy. Each of these drugs binds in the active
site of the coagulation protease and is a competitive inhibitor of
FXa.
The prothrombinase (PTase) enzymatic complex, consisting
of the enzyme FXa, a protein cofactor, Factor Va (FVa),
associated on the surface of negatively charged phospholipid
membranes in the presence of divalent metal ions,2,3 forms a
critical junction of the blood coagulation cascade pathways.4
This complex catalyzes the cleavage of prothrombin (PT),
leading to the formation of thrombin and subsequent clot
formation.5 FXa alone can slowly activate PT, but the rate of
thrombin formation is enhanced by a factor of >105 by the
presence of the cofactor, FVa, and Ca2+ on phospholipid
membranes in the PTase complex.6,7
FXa consists of two chains: the light chain of 139 residues,
and the heavy chain of 305 residues, which contains the
catalytic active site and is connected via a disulfide (Cys122H−
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Cys132L) bridge to the light chain.
8 A wealth of structural data
is available for this protein; over 150 crystal structures of the
protein or protein−ligand complexes have been deposited in
the Brookhaven Protein Data Base (PDB).9 Activated human
FVa consists of a noncovalent calcium-dependent complex
between the heavy chain (Hc: A1 (1−303)−A2 (317−656)
domains) and the light chain (Lc: A3 (1546−1877)−C1
(1878−2036)−C2 (2037−2196) domains), in which the
cofactor binding site is exposed for interaction with FXa.10,11
Several studies have shown that both the Hc and Lc of FVa are
involved in the binding of FXa, and they also give some insights
about FVa residues interacting with FXa.12−16 In addition,
some regions in the Hc of FXa have been suggested to be
important for the interaction with FVa.17−23 High-resolution
crystal structures of FXa are available,24 and homology models
of FVa using the crystal structure of inactivated bovine FVa
(FVai)25 have also been built. Using these two structures,
models of the FXa−FVa complex have been generated that are
consistent with available experimental data.26
The goal of this study is to identify FXa inhibitors that
function within the PTase complex; however, instead of seeking
another active-site directed inhibitor, high-throughput virtual
Figure 1. FXa−FVa binding site: (A) human FXa residues proposed to interact with human FVa, based on the FVa−FXa complex models and the
available experimental data (binding site residues 93−96, 125−129, 164−170, 231−244 are shown in green); (B) residues (green) form part of 3
helices (H1, H2, and H3) and a loop (L1); (C) superposition of human FXa with the FX−FV complex from P. textilis (only superposed human FXa
(red) and P. textilis FV (blue) are shown, and the P. textilis FX structure is not shown for the sake of clarity; the binding interface (shown in green) in
human FXa is proposed to interact with human FVa).
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screening methods are used to identify compounds that are
likely to bind to FXa and alter the interaction between FXa and
FVa, and hence have the potential to down-modulate the PTase
activity in an nonactive site and noncompetitive manner.
■ MATERIALS AND METHODS
FXa−FVa Binding Interface. The active site-inhibited
human FXa structure, solved by X-ray crystallography (PDB
code: 1XKA), was used as the starting structure.24 It has a 2.3 Å
Figure 2. Flowchart showing the Ensemble docking process. Step I: 300 ns MD simulation was performed (pathway a), followed by nearest-
neighbor RMSD clustering (pathway b), generating 15 snapshots. Step II: 244 000 compounds docked, covering 90% of 11.1 million “clean drug-
like” subset from the ZINC database. Step III: Parsed for compounds that bind to the FXa/FVa interface in the crystal structure or at least one of the
11 snapshots; only 532 out of 244 493 docked compounds bind at this interface in the crystal structure. Step IV: Top 80 compounds in the crystal
structure, plus top 40 compounds in each of 11 snapshots selected (520 total) (pathway a) for pharmacophore search with ZincPharmer for larger
compounds (molecular weight (MW) of 280−600 amu), against purchasable ZINC database compounds (pathway b). Step V: Compounds parsed
for druglike properties and redundant compounds removed. Step VI: 37 000 larger compounds docked in 11 snapshots plus crystal structure. Step
VII: Parsed again for compounds that bind to the FXa/FVa interface in the crystal structure or at least one of the 11 snapshots; only 177 out of
36 635 docked larger compounds bind at this interface in the crystal structure. Step VIII: Top 50 compounds in crystal structure, plus top 30
compounds from each of 11 snapshots based on docking scores selected: 288 compounds (after removing redundancy), from which 44 bind to the
crystal structure and others bind to MD snapshots (a); 247 compounds selected that bind to most number of snapshots and only 1 or 2 different
binding sites on the FXa/FVa interface (pathway b). (Out of these, 79 bind to the crystal structure and the others bind to MD snapshots.) Step IX:
Compound selection based on compounds’ availability, cost, chemical diversity, and lack of reactive functional groups. Step X: Analog generation
based on initial positive hits (pathway a); experimental validation of these analogues (pathway b).
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resolution and no gaps in the structure. MD simulations in
previous studies showed that the light chain, which is
connected to a negatively charged phospholipid membrane in
the PTase complex and does not form any interactions with
FVa, is highly flexible in aqueous solution and undergoes
angstroms-wide fluctuations within a few nanoseconds of the
MD.27 To focus on the serine protease domain that interacts
with FVa, this flexible part was removed and only the globular
heavy chain was used in the MD calculations. Homology
models of FVa using the crystal structure of inactivated bovine
FVa (FVai) have been built by other groups.25 Using these
models and the crystal structure of FXa, models of the FXa−
FVa complex have been generated that are in agreement with
available experimental data.26 These models and the available
experimental data were used to identify the regions of FXa that
have been suggested to be important for the interaction with
FVa.
Figure 1A shows the FXa binding surface that is proposed to
interact with FVa, based on the FXa−FVa complex models,
consisting of 28 residues. They form part of 3 helices (H1, H2,
and H3) and one loop (L1), shown in Figure 1B.
Recently, the crystal structure of the FX−FV complex from
the venom of Pseudonaja textilis has been solved.28 The
complex shows specific interactions between the structured A2
and A3 domains of FV and FX. The highly flexible terminal
region following the A2 domain forms nondirectional/non-
specific ionic interactions and lacks a fixed binding mode, and
only a small hydrophobic portion at the end of this region
(IFADIFI) was well-resolved.
The FXa binding interface selected in the current study can
be compared to the crystal structure of the FX:FV complex
from P. textilis. Human FX and FV sequences show an identity
of 50.5% and 53.5% with the respective P. textilis sequences.
The aligned structures of human FXa and P. textilis FX exhibit a
root-mean-square deviation (RMSD) of 2.82 Å (see the
Supporting Information). Figure 1C shows the superposition
of the human FXa crystal structure with the FX−FV complex
from P. textilis (PDB code: 4BXS). The selected human FXa−
FVa binding site consisting of 3 helices and 1 loop also forms
the interface between FX:FV complex from P. textilis (Figure
1C). The FXa−FVa contact region mapped on human FXa
(and shown in Figure 1A) is essentially reproducing the P.
textitlis protein/protein interface.
Molecular Dynamics (MD) Simulations and Cluster-
ing. The dynamics of the FXa heavy chain was characterized
with MD simulations, using the NAMD2 simulation engine.29
The active site ligand and the light chain were removed from
the model. One Ca2+ ion, which was known to be structurally
important,30,31 was kept in the structure. The structure was
protonated according to estimated pKa calculations, using the
Protonate-3D facility in MOE, version 2011,32 with an ionic
concentration of 0.1 mol/L in the Generalized Born/Volume
Integral (GB/VI) electrostatics model.33 A periodic solvation
cube of water molecules was created using the Solvate facility in
MOE-2011. Seven negative Cl− ions were added to neutralize
the system, and the final system consisted of 22 516 atoms, with
6279 water molecules. The system was energy-minimized to a
gradient of 10−5 RMS kcal/mol/Å2, using the CHARMM22
force field34 and an 8−10 Å nonbonded cutoff. NAMD2 input
files were generated using the Dynamics facility in MOE-2011.
A MD integration time step of 2 fs/step was used, holding
covalent bonds in water molecules rigid. A constant temper-
ature of 300 K was maintained throughout the simulation, using
Langevin dynamics. Particle Mesh Ewald (PME) was used for
calculation of the electrostatic interactions with the periodic
boundary conditions. Simulations were performed in the NVT
ensemble. The MD simulation was run on the University of
Tennessee High Performance Computing architecture (New-
ton). A 100 ps initial equilibration was performed, followed by
a 300 ns production trajectory. The resulting trajectories were
analyzed for convergence of temperature and RMSD using perl
scripts for parsing data: Prody v1.235 and Gnuplot v4.6.
Structures of the protein along the MD trajectory were
generated every 50 ps using Prody v1.2, i.e., generating a total
of 6000 structures. Nearest-neighbor RMSD clustering was
used to cluster these structures with Maxcluster,36 using the
RMSD distance between the data point represented by each
structure. Two structures were considered part of the same
cluster if they were closer to each other than the cutoff
threshold distance (i.e., if they were nearest-neighbors). The
entire ensemble docking process flowchart is shown in Figure 2.
High-Throughput Docking Approach. Virtual screening
was performed using the program Autodock Vina37 on 12
structures: 11 structures obtained from the MD clustering
described above, and the FXa crystal structure. The “90%
similarity” “clean drug-like” subset of the ZINC database,38 with
reactive functional groups removed, and that does not violate
any of the Lipinski’s criteria, was used for virtual screening. This
subset contained 244 493 compounds (referenced hereafter as
“Subset A”), covering 90% of the ∼11 million “clean drug-like”
compounds of the ZINC database’s chemical diversity, based
on Tanimoto’s similarity coefficient,39,40 and was precomputed
and directly available from the ZINC database. The procedure
used for clustering the molecules present in this subset involved
sorting the ligands by increasing molecular weights and
progressively selecting compounds that differ from those
previously selected by at least the Tanimoto cutoff (90% in
this case).
These ZINC compounds were converted from the smile
format to the PDB format, using Babel v2.3.341 with the
Generate-3D option. The H atoms in the molecules were
further optimized in MOE-2011, rebalancing the protonation
states by deprotonating strong acids and protonating strong
bases by adding explicit H atoms, if needed. The geometries of
the ligands were optimized using the MMFF94 force field42 in
Babel. The compounds’ coordinates in PDB format were
converted to PDBQT format, using the Prepare Ligand scripts
provided in ADT/MGL Tools v1.5.4.43 The FXa structures in
PDB format from the clustered MD trajectory were also
converted to PDBQT format directly in ADT tools. The
configuration files for each FXa structure, including the docking
grid box dimensions and the box center, used as input for
docking in Autodock Vina, were created using ADT tools.
The Subset A compounds were docked in the crystal
structure and in the first 11 representative structures from MD
trajectory clustering, as indicated in Figure 2, allowing
additional conformations of the ligand by sampling the
rotatable bonds, and keeping the protein’s side chains rigid.
The docking was performed “agnostically,” i.e., binding could
happen anywhere on the protein without imposing a particular
binding site using Autodock Vina on the Newton cluster.
Default values were used for the maximum number of binding
modes to be generated. The value of the exhaustiveness
parameter in Autodock Vina, which directly determines the
extent of sampling of chemical space in the binding site, was set
to a value of 100. Further details about the initial validation
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process of docking sampling/accuracy with docking speed are
given in the Supporting Information.
Docking Results and Secondary Compound Selection.
Perl scripts were used to select the best-scoring binding mode
reported in the AutoDock Vina output for each ligand and to
parse these binding modes in order to identify ligands that bind
in the regions of FXa involved in FVa interactions (Step III in
Figure 2).
The top 80 ranked compounds in the crystal structure and
top 40 ranked compounds in each of the other 11 MD
snapshots (representing a total of 520 compounds) were
identified from the docking calculations. ZincPharmer,44 which
is a pharmacophore search tool for screening the ZINC
database, was used to identify an additional 42 309 compounds
in the ZINC database that are chemically similar to the docking
hits but with larger molecular weights (Step IV in Figure 2).
These compounds were parsed to keep only the drug-like
compounds with properties as defined in the ZINC database,
i.e., MW = 150−500, x log P ≤ 5, net charge between −5 and 5,
≤8 rotatable bonds, polar surface area of <150 Å2, number of H
donors ≤ 5, number of H acceptors ≤ 10, polar desolvation
energy between −400 kcal/mol and 1 kcal/mol, apolar
desolvation energy between −100 kcal/mol and 40 kcal/mol,
and also, to remove any duplicates, giving a total of 36 635
compounds (referenced hereafter as “Subset B”), correspond-
ing to Step V in Figure 2. These compounds were again docked
in the 12 MD snapshot structures, using Autodock Vina on the
UTK’s Newton High Performance cluster with the same
configuration settings as described above. Perl scripts were
again used to parse the docking results for compounds that
bind in the regions of FXa involved in FVa interactions.
Shortlisting Compounds for Experimental Testing.
The results from docking of Subset A (Step II in Figure 2) and
Subset B (Step VI in Figure 2) indicated that compounds can
bind in different sub-binding sites at the FXa/FVa interface, in
different protein MD snapshots. The FXa/FVa interface was
divided into 10 sub-binding sites, based on the clustering of the
binding loci for these compounds.
The computational hits were analyzed using two criteria (in
addition to their predicted binding energies): (i) the number of
MD snapshots to which one specific compound is predicted to
bind, and (ii) the number of sites in the protein where a
compound is predicted to bind. This allows the identification of
compounds that bind to a large number of target structural
variations and binding site(s), or, in other words, to quantify
the promiscuous or specific character of a given compound,
capable of binding to many protein conformations or to only a
few. A value called the “snapshot count” was calculated that
gives the total number of snapshots in which a given compound
binds to the FXa/FVa interface. Compounds found to bind to
most snapshots were checked for the different sub-binding sites
(on the FXa/FVa interface), yielding another value, called the
“binding-site score”, which gives the number of sub-binding
sites that a given compound is docked.
Two lists of compounds were generated for experimental
validations: first, a list that contained 288 compounds,
consisting of the strongest binders in the crystal structure,
and the 11 snapshots, as predicted by Vina docking scores
(shown in Step VIIIa in Figure 2). Second, a list was generated
that contains 247 compounds with “snapshot count” scores of
three and above (i.e., including compounds that successfully
bind to three or more different protein conformations) and
“binding-site scores” of one or two (i.e., removing promiscuous
compounds that bind in many sites in different snapshots),
shown in Step VIIIb of Figure 2. The first list thus contains
compounds that are predicted to bind with the highest binding
affinities at the FXa/FVa interface, and the second list contains
the compounds that can bind to different protein conforma-
tions but, at the same time, are selective for particular binding
sites at the interface.
Visual inspection was performed on the compounds in the
two lists to assess their commercial availability and cost, and to
identify and remove compounds with reactive functional groups
(e.g., aldehydes and alkyl bromides), excessive hydrophobicity
(log P > 5), a lack of functionalization (e.g., polyaromatics with
few or no functional groups) or an excess of functionalization,
the latter two of which would render synthetic analoging
difficult for any follow-up structure−activity relationship (SAR)
studies. The compounds ordered for experimental testing were
selected to sample different sub-binding sites at the interface, as
predicted by the docking, having affordable cost and presenting
desirable chemical features.
Experimental Validation. Structural analogues of the
identified hits were searched from the list of all the compounds
used for docking, including Subsets A and B, using Tanimoto’s
coefficient and the MACCS structural keys fingerprints45 in
MOE-2011. Similar compounds not present in this list were
also identified directly from the ZINC database, using
substructure searching. Further filters described above were
also applied on these compounds to order a second set of
compounds. All compounds were dissolved in 10 mM,
anhydrous, spectroscopic-grade dimethyl sulfoxide (DMSO)
and were stored in sealed vials at −20 °C. Compounds were
diluted in the assay to final concentrations of 5−100 μM. The
final DMSO concentration in the assay was kept constant at
1%.
Initial screening of these compounds for potential FXa
inhibitors was performed using a prothrombinase assay.6 FXa,
FVa, prothrombin, and thrombin were purchased from
Hematologic Technologies. The thrombin and FXa substrates
(S-2238 and S-2222, respectively) were obtained from
diaPharma. Apixaban was purchased from Selleckchem. PTase
assays were performed in 50 mM HEPES, 150 mM NaCl, 0.6
mM MgCl2, 1.6 mM CaCl2, and 1% PEG 6000 at pH 7.4. The
final concentrations of FXa and FVa were 1 nM and 10 nM,
respectively, and the prothrombin substrate concentration was
1.4 μM. PTase activity was measured in a continuous assay that
was initiated by the addition of the substrate prothrombin to
the reaction mixture, and the rate of thrombin generation was
determined by measuring hydrolysis of the thrombin
chromogenic substrate, S-2238 (1 mM) to produce p-
nitroaniline (pNA) that was detected at 405 nm. Replicate
samples were analyzed and the rates were corrected for the very
low rate of hydrolysis of S-2238 by FXa. For this two-step
cascade reaction, in which the product of the first reaction is the
enzyme of the second reaction,46 the activity of the first enzyme
in this cascade (i.e., FXa·FVa) is proportional to dA405/dt
2 and
the absorbance vs time progress curves were fitted to a
quadratic equation, using GraphPad Prism 5.0f. The activity of
isolated FXa was measured using the substrate S-2222.
Binding Sites Analysis. The initial FXa inhibitors
identified by PTase activity assays (and given in the Results
section) were redocked in the binding sites, using MOE-2011
with the CHARMM27 Force-field, allowing protein side chain
flexibility. Additional conformations of the ligand were allowed
by sampling the rotatable bonds. Binding site residues side
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chains were allowed to move away from their original location,
using a tethering weight of 0.1. The GBVI/WSA dG scoring
function47 was used for scoring different poses of the docked
ligand. The top ranked binding poses were energy-minimized
and the compounds’ predicted binding free energies were
calculated using a MM/GBVI-adapted protocol.33
■ RESULTS
MD Simulations and Clustering. The FXa heavy chain
structure including the FXa/FVa binding interface residues was
found to sample different conformations in the MD snapshots,
as shown in Figure 3A. Figure 3B shows the RMSD plot for the
protein backbone over the time course of the trajectory.
Generally, MD simulations are considered stable when the
backbone RMSD is in the low angstrom area.27 However, in the
case of FXa, higher RMSD values (in the range of 2−7 Å) have
been reported.48−50 Based on the RMSD plot in Figure 3B, the
FXa structure converges after the first 100 ns of the trajectory.
Nearest-neighbor RMSD clustering was used to divide the
trajectory into 15 clusters as described in the Materials and
Methods section. Figure 3C shows the superposition of these
structures, also represented on the RMSD plot (Figure 3B)
over the time course of the trajectory. Because of the
constraints on the available computing time, only the first 11
of these clusters were used for docking calculations.
Figure 3. MD Simulations and Clustering. (A) Superposition of 3 FXa structures at different times in the MD trajectory (starting crystal structure is
shown in green, structure at 150 ns is shown in blue, and structure at 300 ns is shown in orange, with binding site residues shown as stick-ball
representations). (B) RMSD plot over the time course of the trajectory. (C) Superposition of representative nonredundant structures from 15
clusters with binding site residues shown in white. Structures in panel (C) are represented on the RMSD plot in panel (B) as black dots.
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High-Throughput Docking. The docking of compound
Subset A in 12 FXa conformations (i.e., the crystal structure
and another 11 representative structures from 15 clusters
obtained from MD) represented a total of ∼2.9 million docking
calculations (Step II in Figure 2). After selecting the best
scoring poses of docked ligands, as predicted by AutoDock
Vina, and parsing these for the selected FXa−FVa binding sites,
it was found that, in the crystal structure, most of the
compounds (99.8%) bind to sites outside of the FXa/FVa
interface, mostly in the protein active site, and only ∼0.2% of
compounds screened (532 compounds in the case of the crystal
structure) bind to FXa within the FXa/FVa interface. As the
MD snapshots sample larger conformational spaces, more
compounds bind at this interface, compared to the number that
bind to the crystal structure. Docking of Subset B compounds
in the 12 structures represented another ∼0.45 million docking
calculations (Step VI in Figure 2). In the case of crystal
structure, only 177 of these compounds (0.5%) bind to FXa
within the FXa/FVa interface, and the higher hit rate compared
to Subset A could be originating from the larger MWs of Subset
B compounds. The number of compounds from Subset A and
Subset B binding within the FXa/FVa interface in the MD
snapshots is provided in the Supporting Information. Figure 4A
shows the comparison between the predicted binding modes of
a compound from Subset A (SBC-160,014) and one from
Subset B (SBC-160,045) binding in the FXa/FVa interface in
the crystal structure (both compounds were subsequently
identified as inhibitors). As one would expect, larger
compounds are found to bind to larger regions on the FXa
surface, and also often (although not in all cases) exhibit better
binding (docking) scores than smaller compounds. The
structures of both these compounds are provided in the
Supporting Information.
Figure 4. Docking analysis. (A) Predicted binding modes of smaller original compound from the Subset A in blue (SBC-160,014) and a larger
similar compound from the Subset B in brown (SBC-160,045) binding in the FXa/Va interface in the crystal structure. The solvent exposed regions
are shown as red on the molecular surface, hydrophobic regions are shown in green, and polar regions are shown in magenta. Larger compounds
cover more binding surface. (B) In the crystal structure, compounds are predicted to bind in five regions: grooves A, B, C, D, and E. (C) Ten (10)
binding sites considered, taking all 12 structures into account.
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Binding Pockets at the FXa/FVa Interface. In the crystal
structure, the compounds that bind in the FXa/FVa interface
were found to bind essentially in five regions, represented by
five grooves, shown in Figure 4B. Taking the docking results
from all snapshots together, the interface was divided into 10
sub-binding sites, as shown in Figure 4C and Table 1, with sub-
binding sites 1, 4, 5, 6, and 9 corresponding to grooves A, B, C,
D, and E in the crystal structure, respectively. Other binding
sites were not observed in the crystal structure but only in MD
snapshots. The 10 binding subsites are thus defined by the
localization of compounds observed in the docking studies, as
opposed to the topological features of the protein surface as
observed in the crystal structure. It was found that compounds
with top snapshot count scores were concentrated in sub-
binding sites 9 (52%), 7 (27%), and 10 (4%), respectively.
Compounds with low binding-site scores of 1 and 2 mostly
bind to sub-binding site 9 as well. This site is relatively large
and present at the center of the binding interface.
The strongest binders, as predicted by Vina docking scores,
were also concentrated in sub-binding sites 9 (43%), 7 (38%),
and 10 (22%). These compounds are weighted heavily from
Subset B (∼91%)compounds that arose from the pharma-
cophore-based search around the best-ranked compounds from
Subset Aand represent an overall higher molecular weight
than that of compounds in Subset A.
Experimental Validation. After employing further filters
to the compounds in the two lists based on the compounds’
availability, cost, chemical similarity, and presence of reactive
functional groups, compounds were obtained for experimental
validation, shown in Step IX in Figure 2. The majority of these
selected compounds were predicted to bind in sites 9 and 7,
with some representation of the remaining binding sites. Of the
first 97 compounds obtained for study, only 41 were fully
soluble in the standard assay buffer. The soluble compounds
were screened for their effect on PTase and FXa enzyme
activity. Initial screening of these compounds at a concentration
of 100 μM was performed in a PTase activity assay measuring
the inhibition of the rate of generation of active thrombin, using
the thrombin specific chromogenic substrate, S-2238. PTase
activity assays identified 19 of the 41 tested compounds as
inhibitors, giving a success rate of 46%. Ten (10) of the 19
inhibitors were predicted to bind well in one or more of the
MD snapshots, but they did not bind to the crystal structure;
these inhibitors would not have been identified if the docking
calculations had been made using only the crystal structure. A
chemical database search identified 22 structural analogues of
SBC-160,042, (Steps Xa and Xb in Figure 2). Nine of these
inhibited PTase activity. Five analogues of SBC-160,029 were
also found, yielding 3 additional inhibitors. From the three sets
of purchased compounds, a total of 31 inhibitors were
identified: 19 were derived from the computational screen
and 12 were based on structural homology without computa-
tional docking.
These compounds inhibit PTase activation of thrombin from
prothrombin in the presence of FVa, but when assayed as direct
FXa inhibitors using the FXa chromogenic peptide substrate, S-
2222, the compounds were not inhibitory, indicating that they
do not bind to the active site of the FXa molecule. Control
experiments also showed that the compounds do not inhibit
thrombin activity toward its chromogenic substrate, S-2238.
The compounds thus appear to be specific inhibitors of the
FXa−FVa activation of prothrombin, and this inhibition is
dependent upon the interaction between FXa and FVa.
Table 1. Ten Sub-binding Sites Identified at the FXa/FVa
Interface and the Corresponding FXa Residues in These




1 Arg-125, Asp-126, Trp-127
2 Val-231, Leu-235
3 Val-231, Ile-238
4 Arg-125, Asp-126, Val-231, Thr-232, Ala-233, Phe-234, Leu-235,
Lys-236, Trp-237, Ile-238, Asp-239, Arg-240
5 Glu-129, Thr-232, Ala-233, Phe-234, Leu-235, Lys-236, Trp-
237, Ile-238
6 Ser-241, Met-242, Lys-243, Arg-93, Phe-94
7 Arg-93, Phe-94, Thr-95, Lys-96
8 Arg-93, Phe-94, Thr-95, Lys-96
9 Arg-125, Asp-126, Trp-127, Ala-128, Glu-129, Asp-164, Arg-165,
Asn-166, Ser-167, Cys-168, Lys-169, Leu-170, Val-231, Thr-
232, Ala-233
10 Asp-164, Arg-165, Asn-166, Ser-167, Cys-168, Lys-169, Leu-170
Figure 5. PTase inhibition. (A) Effect of the identified inhibitors on PTase activity, based on activity measurements, presented as % inhibition vs [I]/
Ki. (B) Plot of the maximum inhibition versus the molecular weights of identified PTase self-limiting inhibitors from Table 2.
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In order to determine the affinities of the compounds and
their maximal inhibition at the saturating inhibitor, the
compounds were assayed as a function of inhibitor concen-
tration at fixed enzyme and substrate concentrations. Ten (10)
of the 31 compounds exhibited a plateau with only partial or
incomplete inhibition of PTase activity as the inhibitor
concentration was increased. As shown in Figure 5A, the
extent of inhibition reaches plateau levels of inhibition, in some
cases well below the maximum level of 100%. This plateau level
of inhibition was maintained even though the inhibitor
concentration was increased to 10 or 20 times the calculated
Ki value. The remaining 21 compounds, although inhibitory,
did not achieve a plateau inhibition at an inhibitor
concentration of 100 μM. The binding affinities of these are
not tight enough to accurately determine the maximal level of
inhibition or the Ki value. Figure 5A, which shows the
percentage inhibition as a function of [I]/Ki, contrasts the
effects of five of the partial inhibitors on PTase activity with the
effect of the anticoagulant apixaban, which is an active site
competitive inhibitor of FXa. Whereas apixaban completely
inhibits activity as the inhibitor concentration is increased, the
characteristic feature of these novel inhibitors is that they
achieve or approach plateau levels of inhibition below that
observed with apixaban. Maximal inhibition, calculated from the
inhibition curves, is 100% for apixaban, 25% for SBC-160,029,
40% for SBC-160,119, 85% for SBC-160,042, and 90%−95%
for SBC-160,109/SBC-160,012.
SBC-160,029 was identified by the computational screen. It is
a member of a substituted tetrazole series and binds to FXa in
four snapshots, including the crystal structure. SBC-160,029
docked exclusively in site 9. SBC-160,029 inhibits PTase
activity to a maximum of ∼25%, with a Ki value of 15 μM
(Table 2). Two analoguesSBC-160,124 and SBC-160,125
(see Table 2)exhibit similar maximal inhibitory activity, with
Ki values of 5 and 20 μM, respectively. SBC-160,120, which is a
larger analogue of SBC-160,029, achieved a plateau inhibition
of 60% with Ki = 30 μM.
Compounds SBC-160,012 and SBC-160,042 were also
identified as site 9 binders, but both compounds also dock
into site 7 in other MD snapshots. SBC-160,012 docks in site 9
in the crystal structure and two other snapshots, but docks to
site 7 in snapshot 10. SBC-160,042 does not dock in the crystal
structure, but docks in site 9 in one snapshot and in site 7 in
another. As listed in Table 2, the 10 partial inhibitors exhibit Ki
values of 5−40 μM, but the maximal inhibition for each
compound varies from 23% (SBC-160,124) to ∼90% (SBC-
160,012, SBC-160,109). Comparing the series of inhibitors in
Table 2 indicated that maximal inhibition increased with
increasing size of the inhibitor. Figure 5B shows the change in
maximum PTase inhibition with the molecular weights of the
compounds. It can be seen that larger compounds inhibit PTase
activity to a greater extent. SBC-160,109, which is a relatively
tight binding analogue of SBC-160,042 with higher molecular
weight, shows greater inhibition, contrasted with SBC-160,119,
which is another SBC-160,042 analogue with lower molecular
weight that exhibits lower maximal inhibition, compared to
SBC-160,042. Interestingly, SBC-160,012, which has a relatively
small molecular weight, is a clear outlier from this trend,
suggesting a complex inhibition mechanism for this compound.
These hits comprise four families of inhibitors, as represented
by SBC-160,010, SBC-160,029, SBC-160,012, and SBC-
160,042, respectively. SBC-160,099, SBC-160,109 and SBC-
160,119 were selected from a panel of structural analogues of
SBC-160,042, whereas SBC-160,120, SBC-160,124, and SBC-
160,125 are analogues of SBC-160,029. The structures of these
compounds are provided in Table 2.
In summary, from ∼3.4 million docking calculations, the
computational results yielded 535 compounds that could
Table 2. Ten Self-Limiting Inhibitors Identified by PTase
Activity Assaysa,b
aThe compounds noted as structural analogues were later subjected to
the virtual screen to identify their hypothetical binding sites. Max %
inhibition and Ki were obtained by fitting activity inhibition as a
function of inhibitor concentration. Binding snapshot 1 represents the
crystal structure. bSymbols used within table: asterisk (*) denotes
binding between sites 7 and 8; dagger (†) indicates data selected as an
analogue of SBC-160,042; and double dagger (‡) indicates data
selected as an analogue of SBC-160,029.
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potentially bind to FXa within the FXa−FVa interaction region.
Thirty one (31) inhibitors were identified, with 10 of them
being represented by four families of inhibitors, exhibiting
partial inhibition of PTase activity in which the extent of
inhibition reaches a maximal plateau value as the enzyme
complex is saturated with inhibitor, so that further increases in
inhibitor concentration do not further inhibit PTase enzyme
activity. We refer to this as “self-limiting inhibition”. Four of
these self-limiting inhibitors originated directly from the initial
docking calculations; the remaining six were selected as
structural analogues of SBC-160,029 and SBC-160,042.
Sub-binding Sites Analysis. Table 2 shows four families
of inhibitors, represented by parent compounds SBC-160,010,
SBC-160,012, SBC-160,042, and SBC-160,029. These com-
pounds were identified as nonactive site inhibitors by PTase
and FXa activity assays. Compounds SBC-160,010 and SBC-
160,029 bind in only sites 7/8 (binding between sites 7 and 8)
and 9, respectively, whereas SBC-160,012 and SBC-160,042 are
able to potentially bind in either site 9 or site 7 in separate
snapshot structures. Table 3 lists the difference in predicted
binding energies calculated using the MM/GBVI protocol in
MOE for the two compounds binding in site 7 and in site 9 in
snapshot 10. The results indicate that compound SBC-160,012
is predicted to bind more strongly in binding site 7 than in
binding site 9. Compound SBC-160,042, however, is predicted
to bind more strongly in binding site 9.
During clustering of the MD trajectory, some clusters
showed relatively higher population of structures, compared
to the others. Table 4 gives the cluster population from which
the representative snapshots (centroid structures) were
selected. Among the snapshots to which these compounds
bind, site 9 was identified in snapshots 2 and 4, and these show
relatively higher cluster populations (10.7% and 4%,
respectively), whereas binding site 7 was identified only in
snapshot 10 that represents a cluster of structures that was
found only 0.5% of the time in the MD trajectory. Snapshot 10
thus represents structures rarely sampled making binding in site
7 for compound SBC-160,012 a rare but possible binding pose,
which is nonetheless quite significant, in terms of the strength
of the interaction (ΔΔG = −3.72).
The major structural changes taking place during the MD
trajectory are seen in loop L1 and helices H2 and H3,
respectively (see the Supporting Information). On the other
hand, helix H1, which was present at the interface, remained
fairly stable throughout the simulation. Site 9 was observed in
the crystal structure, but its shape and structure change
significantly during the MD simulation. Figure 6A shows the
predicted binding mode of a compound identified initially as an
inhibitor that binds to site 9 only in the later snapshots where
the helix H3 is pushed out and not in the crystal structure. Sub-
binding site 7 was not seen in the crystal structure and became
apparent in 3 of the 11 snapshots from the MD trajectory.
Figure 6B shows compound SBC-160,010, which is one of the
compounds initially found as a nonactive site binder docked in
snapshot 3, and how it is not possible for it to bind to the
crystal structure since loop L1 occludes the binding site in the
crystal structure but moves out during MD trajectory, forming
this site. SBC-160,010, inhibits PTase activity by ∼70%.
■ DISCUSSION
Results from clustering the MD trajectory indicate that (i) the
regions of FXa that interact with FVa sample a relatively large
accessible conformational space, as seen in Figures 3A and 3C,
and (ii) ligands are predicted to interact with FXa in a way that
would not necessarily be observed from an analysis that focused
solely on the starting crystal structure. These structural
variations shown in the MD translated into a diverse set of
compounds that potentially bind to the conformations of FXa.
The MD trajectory shows substantial structural changes
taking place at the FXa/FVa interface. The different
conformations sampled by FXa may correspond to different
structures of FXa that can possibly interact with and bind to
FVa, or the protein conformations that are in the process of
equilibration in the FXa−FVa complex. It is also possible that
PT interacts with some regions of loop L1 when binding to the
active site. There are several well-conserved electrostatic
residues present in the loop that may be involved in long-
range interactions with PT, and the flexibility of this loop may
allow PT to “fit” in the FXa binding site.
The novel agnostic docking approach utilized in this study
identified 10 possible binding pockets at the FXa/FVa interface,
shown in Figure 4C. Sub-binding site 9, a relatively large area at
the center of the FVa binding interface, was found to be a major
binding site for compounds. Most of the nonactive site
Table 3. Differences in Binding Free Energy for Selected
Compounds in Binding Site 9 and Binding Site 7 in
Snapshot 10
compound ΔΔG (ΔG site 7 − ΔG site 9) (kcal/mol)
SBC-160,012 −3.72
SBC-160,042 +2.38
Table 4. Cluster Population for the Binding Snapshots of
Compounds SBC-160,010, SBC-160,012, SBC-160,029, and
SBC-160,042







Figure 6. Structural variations with MD. Superposition of loop
backbones in the FXa−FVa interacting region. The FXa crystal
structure is shown in yellow, whereas snapshots from the MD
trajectory are shown in blue. (A) SBC-160,042 (cyan) binds to sub-
binding site 9 in snapshot 4, where the helix 3 (H3) is pushed out, and
not in the crystal structure. (B) SBC-160,010 (cyan) binds to sub-
binding site 7/8 in snapshot 3, where the loop 1 (L1) moves out,
opening the binding site.
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inhibitors identified by PTase activity assays are predicted to
bind to site 9, indicating the importance of this site for the
interaction of FXa with FVa. Compounds that bind at this site
interact with residues from all three helices of interest (H1, H2,
and H3) and inhibit PTase activity. This site was observed in
the crystal structure, but its shape and structure change
significantly during the MD simulation. Figure 6A shows
compound SBC-160,042 that was identified as a self-limiting
inhibitor with a maximal inhibition of PTase activity at
saturating concentrations of ∼80%. SBC-160,042 is predicted
to bind in site 9, but the binding would not have been identified
from the crystal structure searches alone.
The binding studies indicated that some compounds had the
potential of binding in more than one site. SBC-160,012 and
SBC-160,042 are two notable examples, and both compounds
are capable of binding in sites 7 and 9 in different snapshot
structures. Tables 3 and 4 indicate that, while site 9 (snapshots
2, 4, 5, and 9) is sampled ∼3 to ∼20-fold more often than site 7
(snapshot 10), the predicted binding affinity of compound
SBC-160,012 (predicted to bind in both sites 7 and 9) is
stronger in site 7 by 3.72 kcal/mol. Hence, this compound’s
predicted binding site is difficult to assess: site 9 is more often
accessible but binding in site 7 is more stable. It is theoretically
possible that the compound may bind at both sites and possibly
simultaneously. Inversely, binding of compound SBC-160,042
is predicted to bind most likely in binding site 9, since the
predicted binding free energy of this compound is stronger in
site 9 than in site 7, by 2.38 kcal/mol.
From the crystal structure of the prothrombinase complex,
from the venom of P. textilis,28 it can be observed that there are
binding pockets present at the interface of FX and FV that
could possibly be targeted by small molecules. Figures 7A and
7B show the superposition of human FXa (crystal structure)
bound with a site 9 inhibitor (SBC-160,045) in its predicted
binding mode, with the FX-FV complex from P. textilis. The
similarity of the P. textilis structure and the human FXa
structure suggests that the binding sites investigated here for
human FXa are relevant to the modulation of FXa−FVa
interaction. Site 9 binding compounds discovered from the
agnostic computational approach bind directly at the interface
of FXa and the A2/A3 domains of FV. The observation that
these compounds inhibit PTase activity supports the hypothesis
that they may interfere with the specific interactions between
these proteins. Figures 7C and 7D show the superposition of
the P. textilis FX−FV complex with human FXa (snapshot 10
from MD simulation) containing the inhibitor SBC-160,062,
which inhibits activity by 20% ± 7% and is predicted to bind in
site 7. In this snapshot, the flexible loop L1 folds to form site 7,
which is not seen in the crystal structure of human or P. textilis
FXa. As seen in this MD snapshot, binding of ligands in site 7
can interfere with the interactions between human FXa and the
small hydrophobic portion of the terminal region in FV. The
structures of these compounds are given in the Supporting
Information.
The initial objective of this study was to determine if an
agnostic virtual screening approach could be used to identify
potential binding sites on FXa for compounds that could inhibit
PTase activity. This objective has been met as shown in Figure
5A and Table 2. Larger compounds are found to bind to larger
sites on the FXa surface, with docking scores that predict
tighter binding compared to smaller compounds, which could
prove advantageous in modulating the FXa−FVa protein−
protein interaction. Figure 5B supports the hypothesis in that
larger compounds are better inhibitors of PTase activity.
In future studies, lead optimization can be aided by the
chemical structures and binding poses of positive hits predicted
to bind at sites 7, 9, and 10. Library design can be based on
compound modifications guided by pharmacophore features
associated with active compounds while, at the same time,
avoiding those features associated with inactive compounds
(e.g., volume exclusion). It should also be possible to
differentiate between binding in site 7 and site 9 from the
experimental testing of compounds originating by crystallog-
raphy, as well as by directed mutagenesis studies that would
affect the predicted potential binding modes identified
computationally. These compounds will be used to identify
new hits and to develop structure−activity relationships (SARs)
in order to identify more potent and selective lead compounds
against PTase.
■ CONCLUSION
This study has used an ensemble docking approach to identify
structural variations of FXa using molecular dynamics (MD)
simulations, and it has targeted these conformations with
compounds that specifically bind to the FXa/FVa interface to
modulate the PTase activity in a nonactive site-dependent
manner. In contrast to competitive active site inhibitors, which
completely inhibit enzyme activity at saturating inhibitor
concentrations, these nonactive site PTase inhibitors exhibit a
plateau in inhibition that is referred to as “self-limiting
inhibition”. PTase activity assays identified a total of 31
compounds as inhibitors. From these nonactive site inhibitors,
10 compounds achieved self-limiting inhibition of PTase, 8 of
Figure 7. Site 9 and 7 in FX-FV complex. (A) Superposition of human
FXa (crystal structure) bound with a site 9 inhibitor (SBC-160,045),
with the FX−FV complex from P. textilis. Only superposed human
FXa and P. textilis FV are shown, and the P. textilis FX structure is not
shown for the sake of clarity. The human FXa structure is shown in
red; the A2 domain from P. textilis FV is shown in cyan; the A3
domain from P. textilis FV is shown in green; and the flexible terminal
region in FV is shown in purple. The site 9 inhibitor binds directly at
the interface of FXa and A2/A3 domains of FV. (B) 90° rotation of
the structure shown in panel (A). (C) Superposition of human FXa
(snapshot 10 from MD simulation) bound with site 7 inhibitor (SBC-
160,062), with the FX-FV complex (the hydrophobic portion of the
terminal region is shown in stick conformation). (D) 90° rotation of
the structure shown in panel (C).
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which would not have been identified using only the crystal
structure of the protein.
This study exemplifies a successful MD simulation and high-
throughput virtual screening approach to drug discovery
targeting a protein−protein complex. Amaro et al. showed
the importance of employing MD to account for protein
flexibility in the discovery of new molecules for African sleeping
sickness.51 Here, we apply a similar ensemble docking
approach, but use a larger compound database, covering a
larger chemical space, with ∼3.4 million docking calculations
completed in total. In future studies, the same approach can be
extended to even larger compound databases, covering millions
of compounds and targeting multiple protein targets, using
massive high-throughput screenings on supercomputers such as
TITAN.52,53 This can increase dramatically the number and
diversity of compounds that can be identified while, at the same
time, taking into account the inherent flexibility and the




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jcim.5b00596.
Number of compounds from Subset A and Subset B
binding within the FXa/FVa interface (Table S1);
superimposed structures of human FXa and FX from P.
textilis (Figure S1); validation of docking sampling/
accuracy vs docking speed (section S1); percentage
similarity at different exhaustiveness values (Figure S2);
superposition of crystal structure and MD snapshot
(Figure S3); structural information for compounds
shown in Figures 4 and 7 (Figure S4) (PDF)
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